Harman Finochem Limited
Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $11.4M Total Trade · DGFT Verified
Harman Finochem Limited is an Indian pharmaceutical exporter with a total trade value of $11.4M across 3 products in 3 therapeutic categories. Based on 526 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Metformin ($6.9M), Allopurinol ($3.4M), Bisoprolol ($1.1M).
Harman Finochem Limited — Export Portfolio & Destination Treemap
Who is Harman Finochem Limited? — Company Overview & Market Position
Harman Finochem Limited, established on March 17, 1983, is a Mumbai-based pharmaceutical company specializing in the manufacturing and export of Active Pharmaceutical Ingredients (APIs) and chemical intermediates. The company operates under the Corporate Identification Number (CIN) U24110MH1983PLC029560 and is registered as a public limited company in Mumbai, Maharashtra.
The authorized share capital of Harman Finochem Limited is ₹50 million, with a paid-up capital of ₹47.636 million, reflecting a promoter holding of approximately 92.83% as of 2023. The company employs around 1,772 individuals as of April 9, 2024. Harman Finochem Limited's website is www.harmanfinochem.com.
What Does Harman Finochem Limited Export? — Product Portfolio Analysis
Top Products by Export Value
Harman Finochem Limited Therapeutic Categories — 3 Specializations
Harman Finochem Limited operates across 3 therapeutic categories, with Diabetes & Endocrine (60.3%), Lipid & Metabolism (29.7%), Cardiovascular (10.0%) representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Diabetes & Endocrine
1 products · 60.3% · $6.9M
Lipid & Metabolism
1 products · 29.7% · $3.4M
Cardiovascular
1 products · 10.0% · $1.1M
Product Portfolio — Top 3 by Export Value
Harman Finochem Limited exports 3 pharmaceutical products across 3 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Metformin | Diabetes & Endocrine | $6.9M | 295 | 1.5% | 15 |
| 2 | Allopurinol | Lipid & Metabolism | $3.4M | 80 | 0.7% | 6 |
| 3 | Bisoprolol | Cardiovascular | $1.1M | 151 | 1.4% | 9 |
Harman Finochem Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $11.4M. The top category is Diabetes & Endocrine (60.3% of portfolio), followed by Lipid & Metabolism (29.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Key Metrics
Top Categories
Top Export Routes
Related Analysis
Need Detailed Data?
Shipment-level records, pricing & buyer contacts for Harman Finochem Limited.
Request DemoHarman Finochem Limited — Corporate Profile & Information
Headquarters, ownership, manufacturing facilities, and key leadership
1Corporate Overview
Harman Finochem Limited, established on March 17, 1983, is a Mumbai-based pharmaceutical company specializing in the manufacturing and export of Active Pharmaceutical Ingredients (APIs) and chemical intermediates. The company operates under the Corporate Identification Number (CIN) U24110MH1983PLC029560 and is registered as a public limited company in Mumbai, Maharashtra.
The authorized share capital of Harman Finochem Limited is ₹50 million, with a paid-up capital of ₹47.636 million, reflecting a promoter holding of approximately 92.83% as of 2023. The company employs around 1,772 individuals as of April 9, 2024. Harman Finochem Limited's website is www.harmanfinochem.com.
2Manufacturing Facilities
Harman Finochem Limited operates two state-of-the-art manufacturing facilities in Aurangabad, Maharashtra, with a combined production capacity of 350,000 liters. These facilities are compliant with current Good Manufacturing Practices (cGMP) and have been inspected by international regulatory bodies, including the USFDA, EU, PMDA, KFDA, TGA, ANVISA, and PIC/s. (pharmasource.global)
3Key Leadership
The company is led by Chairman and Managing Director Mr. Bhupinder Singh Manhas, who founded Harman Finochem Limited in 1983. Other key executives include Inderjeet Kaur Bhupinder Singh, Harpreet Singh Bhupinder Singh, Gurpreet Singh Minhas, and Savreen Minhas.
Where Does Harman Finochem Limited Export? — Destination Intelligence
Regulated market presence, emerging market penetration, and geographic strategy
1Regulated Markets
Harman Finochem Limited has a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities are inspected and comply with cGMP norms as per USFDA, ICH Q7A, TGA, PIC, WHO-GMP, Schedule M, and Japanese Foreign Accreditation. (pharmasource.global) The company has submitted Drug Master Files (DMFs) for several APIs to the USFDA and is awaiting facility approval.
2Emerging Markets
Harman Finochem Limited has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's manufacturing facilities are WHO-GMP certified, facilitating access to these regions.
3Geographic Strategy
The company's export portfolio is highly concentrated, with the top five products accounting for 100% of total exports. This indicates a lack of diversification, which may expose Harman Finochem Limited to risks associated with market fluctuations in these specific products.
Harman Finochem Limited — Manufacturing & Regulatory Profile
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
1FDA Status
Harman Finochem Limited has submitted Drug Master Files (DMFs) for several APIs to the USFDA and is awaiting facility approval. The company's manufacturing facilities are inspected and comply with cGMP norms as per USFDA standards. (pharmasource.global)
2WHO & EU GMP
The company's manufacturing facilities are WHO-GMP certified, facilitating access to emerging markets. Additionally, Harman Finochem Limited has received EU GMP approval for its formulation facility of Oral Solid Dosages.
3CDSCO & Indian Regulatory
Harman Finochem Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers. The company has also been awarded the certificate of recognition as an export house by the Ministry of Commerce, Government of India, for its meritorious contribution in the field of API exports.
4Recent Regulatory Actions
As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Harman Finochem Limited.
Harman Finochem Limited — Competitive Positioning Among Indian Pharma Exporters
Market share comparison, key differentiators, and strategic analysis
1Competitive Landscape
Harman Finochem Limited operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share data is not available, the company's focus on APIs and chemical intermediates positions it alongside other manufacturers in the sector.
2Key Differentiators
Harman Finochem Limited's key differentiators include its specialization in over 45 APIs, including Metformin HCl, Fenofibrate, Divalproex Sodium, Riboflavin Phosphate Sodium, and Glycopyrrolate/Glycopyrronium bromide. The company operates two GMP-certified manufacturing sites in Aurangabad, maintaining a combined production capacity of 350,000 liters.
3Strategic Position
Harman Finochem Limited's current strategic direction focuses on the manufacturing and export of APIs, with an emphasis on quality and compliance with international standards. The company's future outlook includes expanding its product portfolio and exploring new markets to enhance its global presence.
Buyer Due Diligence Brief — Evaluating Harman Finochem Limited as a Supplier
Track record assessment, certifications to verify, and pre-order checks
1Supplier Assessment
Harman Finochem Limited has a track record of exporting APIs to over 75 countries worldwide. The company's manufacturing facilities are inspected and comply with cGMP norms as per USFDA, ICH Q7A, TGA, PIC, WHO-GMP, Schedule M, and Japanese Foreign Accreditation. (pharmasource.global) The company has been awarded the certificate of recognition as an export house by the Ministry of Commerce, Government of India, for its meritorious contribution in the field of API exports.
2Certifications to Verify
Importers should verify the following certifications when considering Harman Finochem Limited as a supplier:
- FDA Registration: Confirm the company's registration status with the US Food and Drug Administration (FDA) through the FDA's official website.
- WHO-GMP Certification: Verify the World Health Organization's Good Manufacturing Practices (WHO-GMP) certification by consulting the WHO's official website.
- EU GMP Certification: Check the European Union's Good Manufacturing Practices (EU GMP) certification through the European Medicines Agency (EMA) website.
- ISO Certification: Ensure the company holds relevant ISO certifications by reviewing the International Organization for Standardization's official website.
3Due Diligence Checklist
When conducting due diligence on Harman Finochem Limited, consider the following steps:
- Verify Regulatory Compliance: Confirm the company's compliance with relevant regulatory bodies, including the FDA, WHO, EU, and CDSCO.
- Assess Financial Health: Review the company's financial statements and credit history to evaluate its financial stability.
- Evaluate Manufacturing Capabilities: Inspect the manufacturing facilities to ensure they meet required standards and certifications.
- Review Product Portfolio: Analyze the company's product offerings to ensure they align with your requirements.
- Check References: Contact existing clients and partners to gather feedback on the company's performance and reliability.
Be cautious of any discrepancies in certifications or regulatory approvals, as these may indicate potential issues.
Frequently Asked Questions — Harman Finochem Limited
How many pharmaceutical products does Harman Finochem Limited export from India?
Harman Finochem Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Metformin ($6.9M), Allopurinol ($3.4M), Bisoprolol ($1.1M). Total export value is $11.4M.
What is Harman Finochem Limited's total pharmaceutical export value?
Harman Finochem Limited's total pharmaceutical export value is $11.4M, based on 526 verified shipments recorded in Indian Customs (DGFT) data.
What therapeutic categories does Harman Finochem Limited cover?
Harman Finochem Limited exports across 3 therapeutic categories. The largest are Diabetes & Endocrine (60.3%, 1 products), Lipid & Metabolism (29.7%, 1 products), Cardiovascular (10.0%, 1 products).
Get Full Harman Finochem Limited Export Intelligence
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Official References & Regulatory Resources
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Matching: Harman Finochem Limited identified across shipments using name normalization.
- 2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 3.Market Share: Calculated per product as Harman Finochem Limited's capped value divided by total Indian exports for that product.
- 4.Shipment Count: Based on 526 individual customs records matching Harman Finochem Limited.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Products Tracked
3 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Data Source & Methodology
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.